FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) and Microsoft Japan Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Hitoshi Yoshida, hereinafter Microsoft Japan) are social. We will start collaboration to deal with medical and nursing care risks due to aging, which is an issue, and to provide solutions that will lead to the solution of the issues.

As the first collaboration, FRONTEO will develop FRONTEO's dementia diagnosis support AI system on the cloud platform Microsoft Azure.The system supports the diagnosis of dementia through natural conversations rather than specialized conversations and interviews, thereby early detection of potential dementia patients who are increasing with the rapid progress of aging. , It is possible to lead to treatment at a specialized medical institution at an early stage.

This system aims to obtain regulatory approval as a language-based AI medical device that is unique in order to provide it to hospitals and clinics nationwide.

Comment from Mr. Noriaki Tsunoda, President and CEO of Kyowa Pharmaceutical Industry Co., Ltd.

It is very encouraging that Microsoft Japan will participate as a new partner in the dementia diagnosis support AI system that we and FRONTEO have been promoting to become a CNS (Central Nervous System) total solution company.We believe that the cooperation of the three companies to tackle dementia, which is a national issue, is of great significance for the progress of digital healthcare in Japan.

Following the dementia diagnosis support AI system, we are considering providing other life science AI products provided by FRONTEO, the article search AI "Amanogawa", and the drug discovery support AI "Cascade Eye" on Azure. By building these systems on Azure, it is possible to provide benefits such as cost control to companies and research institutes considering introduction, both in the initial stage and in operation.

In addition, Microsoft Japan will support the introduction of the system in cooperation with FRONTEO as a joint sales solution for medical institutions and pharmaceutical companies in Japan that will introduce Azure.As a result, it is expected to be used in a wide range of medical institutions such as medical research institutes and university hospitals.

In the future, the two companies will develop AI solutions in the fields of drug discovery and long-term care to address medical and long-term care risks in a super-aging society and promote digital transformation in the medical field.

■ About Microsoft Japan Co., Ltd. URL:https://www.microsoft.com/ja-jp/

Microsoft Japan Co., Ltd. is a Japanese corporation of Microsoft Corporation.Microsoft enables digital transformation in the age of intelligent cloud and intelligent edge. Our corporate mission is "Empower every person and every organization on the planet to achieve more."

■ FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO is an in-house developed AI engine "KIBIT" that specializes in natural language processing.^®"And" concept encoder^®Is a data analysis company that supports the business of a company by extracting meaningful and important information from a huge amount of text data using. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic evidence disclosure)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field from 8, and use AI to "turn text data into knowledge" to support drug discovery. , Dementia diagnosis support, financial, personnel, sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

* Microsoft and Azure are registered trademarks or trademarks of Microsoft Corporation in the United States and other countries.

* Other company names and product names mentioned are registered trademarks or trademarks of each company.